

Bruno Imbimbo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2551447/publications.pdf>

Version: 2024-02-01

224
papers

10,471
citations

26630
56
h-index

42399
92
g-index

236
all docs

236
docs citations

236
times ranked

11646
citing authors

#	ARTICLE	IF	CITATIONS
1	A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. <i>Alzheimer's and Dementia</i> , 2022, 18, 1008-1037.	0.8	29
2	The β -Secretase BACE1 in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 745-756.	1.3	336
3	Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 325-337.	1.8	2
4	Brain Amyloid Deposition in Late-Life Depression. <i>Biological Psychiatry</i> , 2021, 89, e41-e42.	1.3	3
5	Accelerating Alzheimer's disease drug discovery and development: what's the way forward?. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 727-735.	5.0	9
6	Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression. <i>Journal of Affective Disorders</i> , 2021, 286, 275-281.	4.1	9
7	Can platelet activation result in increased plasma $A\beta$ levels and contribute to the pathogenesis of Alzheimer's disease?. <i>Ageing Research Reviews</i> , 2021, 71, 101420.	10.9	15
8	Can Anti- $A\beta$ -amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?. <i>Neurology: Genetics</i> , 2021, 7, e535.	1.9	10
9	What have we learned from past failures of investigational drugs for Alzheimer's disease?. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1175-1182.	4.1	13
10	Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 919-933.	4.1	22
11	Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer's disease or should they be looking elsewhere?. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 1241-1251.	5.0	15
12	Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 213-228.	10.1	73
13	Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer's disease?. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12004.	3.7	7
14	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020, 11, 456.	4.8	201
15	Drug-induced reductions in brain amyloid- β levels may adversely affect cognition and behavior by a disruption of functional connectivity homeostasis. <i>Neurodegenerative Disease Management</i> , 2019, 9, 189-191.	2.2	1
16	Investigational BACE inhibitors for the treatment of Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 967-975.	4.1	94
17	Structure-activity relationships of flurbiprofen analogues as stabilizers of the amyloidogenic protein transthyretin. <i>Journal of Structural Biology</i> , 2019, 208, 165-173.	2.8	11
18	Time to test antibacterial therapy in Alzheimer's disease. <i>Brain</i> , 2019, 142, 2905-2929.	7.6	89

#	ARTICLE	IF	CITATIONS
19	Do anti-amyloid- β^2 drugs affect neuropsychiatric status in Alzheimer's disease patients?. Ageing Research Reviews, 2019, 55, 100948.	10.9	24
20	Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?. Expert Review of Neurotherapeutics, 2019, 19, 599-602.	2.8	32
21	Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs. Expert Opinion on Pharmacotherapy, 2019, 20, 1091-1107.	1.8	15
22	Disease-modifying therapies for tauopathies: agents in the pipeline. Expert Review of Neurotherapeutics, 2019, 19, 397-408.	2.8	15
23	A critical appraisal of amyloid- β^2 -targeting therapies for Alzheimer's disease. Nature Reviews Neurology, 2019, 15, 73-88.	10.1	666
24	Are antibodies directed against amyloid- β^2 (A β^2) oligomers the last call for the A β^2 hypothesis of Alzheimer's disease?. Immunotherapy, 2019, 11, 3-6.	2.0	50
25	Amyloid- β^2 immunotherapy for alzheimer disease: Is it now a long shot?. Annals of Neurology, 2019, 85, 303-315.	5.3	126
26	Amyloid deposition in a mouse model humanized at the transthyretin and retinol-binding protein 4 loci. Laboratory Investigation, 2018, 98, 512-524.	3.7	6
27	The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. Expert Opinion on Biological Therapy, 2018, 18, 25-35.	3.1	34
28	BACE inhibitors in clinical development for the treatment of Alzheimer's disease. Expert Review of Neurotherapeutics, 2018, 18, 847-857.	2.8	66
29	Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study. Journal of Alzheimer's Disease, 2018, 65, 989-1000.	2.6	42
30	CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 42-51.	3.0	13
31	Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline. Journal of Alzheimer's Disease, 2017, 59, 121-130.	2.6	41
32	Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging. Journal of the American Medical Directors Association, 2017, 18, 89.e1-89.e8.	2.5	126
33	Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review. Journal of Alzheimer's Disease, 2017, 59, 815-849.	2.6	249
34	Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation. International Journal of Molecular Sciences, 2017, 18, 184.	4.1	6
35	Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. BioMed Research International, 2016, 2016, 1-15.	1.9	138
36	Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?. International Psychogeriatrics, 2016, 28, 1111-1124.	1.0	19

#	ARTICLE	IF	CITATIONS
37	Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 973-979.	2.6	23
38	Emerging drugs to reduce abnormal β -amyloid protein in Alzheimer's disease patients. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 377-391.	2.4	54
39	Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy. <i>Immunotherapy</i> , 2016, 8, 1119-1134.	2.0	61
40	Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 259-277.	2.8	35
41	Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy?. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 457-461.	1.8	17
42	Coffee Consumption Habits and the Risk of Mild Cognitive Impairment: The Italian Longitudinal Study on Aging. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 889-899.	2.6	51
43	Alternative pharmacological treatment options for agitation in Alzheimer's disease. <i>Geriatric Care</i> , 2015, 1, .	0.2	1
44	Age-related hearing impairment and frailty in Alzheimer's disease: interconnected associations and mechanisms. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 113.	3.4	67
45	CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid. <i>Neuroscience</i> , 2015, 302, 112-120.	2.3	39
46	CHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinol-binding protein loci. <i>FEBS Letters</i> , 2015, 589, 849-856.	2.8	14
47	Progresses in treating agitation: a major clinical challenge in Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2581-2588.	1.8	43
48	Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 973-986.	2.8	42
49	Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 405-419.	3.0	86
50	Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?. <i>Current Opinion in Psychiatry</i> , 2014, 27, 128-137.	6.3	86
51	Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1465-1476.	3.1	63
52	CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice. <i>Neuroscience</i> , 2014, 266, 13-22.	2.3	8
53	Electrophysiological and metabolic effects of CHF5074 in the hippocampus: Protection against in vitro ischemia. <i>Pharmacological Research</i> , 2014, 81, 83-90.	7.1	22
54	Pharmacological targeting of the β -amyloid precursor protein intracellular domain. <i>Scientific Reports</i> , 2014, 4, 4618.	3.3	19

#	ARTICLE	IF	CITATIONS
55	Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neuroscience, 2013, 14, 44.	1.9	58
56	Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age, 2013, 35, 441-453.	3.0	35
57	Receptor for Advanced Glycation End Products Contributes to Postnatal Pulmonary Development and Adult Lung Maintenance Program in Mice. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 164-171.	2.9	32
58	Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors. FEBS Letters, 2013, 587, 2325-2331.	2.8	21
59	O3-06-05: Sustained cognitive benefit in patients with mild cognitive impairment (MCI) upon prolonged treatment with CHF5074. , 2013, 9, P530-P530.		2
60	Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging. Alzheimer's and Dementia, 2013, 9, 113-122.	0.8	140
61	Pharmacokinetics and Pharmacodynamics of CHF5074 After Short-term Administration in Healthy Subjects. Alzheimer Disease and Associated Disorders, 2013, 27, 278-286.	1.3	34
62	<scp>CHF</scp>5074 restores visual memory ability and preâ€synaptic cortical acetylcholine release in preâ€plaque Tg2576 mice. Journal of Neurochemistry, 2013, 124, 613-620.	3.9	16
63	Î³-Secretase Pharmacology: What Pharmacology Will Work for Alzheimer's Disease?. International Journal of Alzheimer's Disease, 2013, 2013, 1-2.	2.0	1
64	CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study. Current Alzheimer Research, 2013, 10, 742-753.	1.4	73
65	Therapeutic effect of CHF5074, a new Î³-secretase modulator, in a mouse model of scrapie. Prion, 2012, 6, 62-72.	1.8	11
66	Immunotherapy for Alzheimerâ€™s disease: from anti-Î²-amyloid to tau-based immunization strategies. Immunotherapy, 2012, 4, 213-238.	2.0	121
67	Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimerâ€™s disease patients. Future Neurology, 2012, 7, 395-401.	0.5	1
68	Advances in the identification of Î³-secretase inhibitors for the treatment of Alzheimer's disease. Expert Opinion on Drug Discovery, 2012, 7, 19-37.	5.0	45
69	Solanezumab for the treatment of mild-to-moderate Alzheimerâ€™s disease. Expert Review of Clinical Immunology, 2012, 8, 135-149.	3.0	79
70	Metabolic-Cognitive Syndrome: Metabolic Approach for the Management of Alzheimer's Disease Risk. Journal of Alzheimer's Disease, 2012, 30, S1-S4.	2.6	10
71	Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective?. International Journal of Geriatric Psychiatry, 2012, 27, 1218-1238.	2.7	90
72	Monoclonal antibodies against Î²-amyloid (AÎ²) for the treatment of Alzheimer's disease: the AÎ² target at a crossroads. Expert Opinion on Biological Therapy, 2011, 11, 679-686.	3.1	40

#	ARTICLE	IF	CITATIONS
73	Therapeutic intervention for Alzheimer's disease with β -secretase inhibitors: still a viable option?. Expert Opinion on Investigational Drugs, 2011, 20, 325-341.	4.1	86
74	Gerontechnology for Demented Patients: Smart Homes for Smart Aging. Journal of Alzheimer's Disease, 2011, 23, 143-146.	2.6	48
75	Diet and Alzheimer's disease risk factors or prevention: the current evidence. Expert Review of Neurotherapeutics, 2011, 11, 677-708.	2.8	231
76	β -Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes. Current Topics in Medicinal Chemistry, 2011, 11, 1555-1570.	2.1	168
77	Mediterranean Diet in Predementia and Dementia Syndromes. Current Alzheimer Research, 2011, 8, 520-542.	1.4	73
78	The β -Secretase Modulator CHF5074 Restores Memory and Hippocampal Synaptic Plasticity in Plaque-Free Tg2576 Mice. Journal of Alzheimer's Disease, 2011, 24, 799-816.	2.6	53
79	Comparison of Pharmacological Modulation of APP Metabolism in Primary Chicken Telencephalic Neurons and in a Human Neuroglioma Cell Line. Journal of Molecular Neuroscience, 2011, 43, 257-267.	2.3	14
80	The β -Secretase Modulator CHF5074 Reduces the Accumulation of Native Hyperphosphorylated Tau in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Molecular Neuroscience, 2011, 45, 22-31.	2.3	25
81	Metabolic Syndrome, Mild Cognitive Impairment and Dementia. Current Alzheimer Research, 2011, 8, 492-509.	1.4	67
82	Anti- β -Amyloid Immunotherapy for Alzheimer's Disease: Focus on Bapineuzumab. Current Alzheimer Research, 2011, 8, 808-817.	1.4	51
83	Interacting with β -Secretase for Treating Alzheimer's Disease: From Inhibition to Modulation. Current Medicinal Chemistry, 2011, 18, 5430-5447.	2.4	26
84	β -secretase inhibitors for treating Alzheimer's disease: rationale and clinical data. Clinical Investigation, 2011, 1, 1175-1194.	0.0	2
85	Aluminium in the Diet, Cognitive Decline and Dementia. , 2011, , 2829-2850.		0
86	Metabolic Syndrome and Cognitive Impairment: Current Epidemiology and Possible Underlying Mechanisms. Journal of Alzheimer's Disease, 2010, 21, 691-724.	2.6	139
87	Aluminum in the Diet and Alzheimer's Disease: From Current Epidemiology to Possible Disease-Modifying Treatment. Journal of Alzheimer's Disease, 2010, 20, 17-30.	2.6	78
88	Nutraceutical Properties of Mediterranean Diet and Cognitive Decline: Possible Underlying Mechanisms. Journal of Alzheimer's Disease, 2010, 22, 715-740.	2.6	149
89	CHF5074, a Novel β -Secretase Modulator, Restores Hippocampal Neurogenesis Potential and Reverses Contextual Memory Deficit in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 159-173.	2.6	71
90	Peripheral Antioxidant Markers in Mild Cognitive Impairment and its Progression to Dementia. Journal of Alzheimer's Disease, 2010, 21, 1179-1183.	2.6	6

#	ARTICLE	IF	CITATIONS
91	Dietary Unsaturated Fatty Acids and Risk of Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 21, 867-870.	2.6	12
92	Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?. Frontiers in Aging Neuroscience, 2010, 2, .	3.4	119
93	Are β -secretase inhibitors detrimental for Alzheimer's disease patients?. Journal of Alzheimer's Disease, 2010, 22, 401-404.	2.6	10
94	Bapineuzumab: anti- β -amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy, 2010, 2, 767-782.	2.0	52
95	Towards Disease-Modifying Treatment of Alzheimer's Disease: Drugs Targeting β -Amyloid. Current Alzheimer Research, 2010, 7, 40-55.	1.4	109
96	Late-Life Depression, Mild Cognitive Impairment, and Dementia: Possible Continuum?. American Journal of Geriatric Psychiatry, 2010, 18, 98-116.	1.2	502
97	Polymorphisms in Glutathione S-Transferase Omega-1 Gene and Increased Risk of Sporadic Alzheimer Disease. Rejuvenation Research, 2010, 13, 645-652.	1.8	23
98	Interleukin 6 γ 174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 177-182.	4.8	27
99	REVIEW: β -Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State. CNS Neuroscience and Therapeutics, 2010, 16, 272-284.	3.9	63
100	Is Insulin Resistant Brain State a Central Feature of the Metabolic-Cognitive Syndrome?. Journal of Alzheimer's Disease, 2010, 21, 57-63.	2.6	69
101	Aluminum in the diet and Alzheimer's disease: from current epidemiology to possible disease-modifying treatment. Journal of Alzheimer's Disease, 2010, 20, 17-30.	2.6	42
102	Polyunsaturated Fatty Acid and S-Adenosylmethionine Supplementation in Predementia Syndromes and Alzheimer's Disease: A Review. Scientific World Journal, The, 2009, 9, 373-389.	2.1	24
103	An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease. Expert Opinion on Investigational Drugs, 2009, 18, 1147-1168.	4.1	88
104	Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists. Medicinal Research Reviews, 2009, 29, 867-902.	10.5	35
105	CHF5074, a novel β -secretase modulator, attenuates brain β -amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. British Journal of Pharmacology, 2009, 156, 982-993.	5.4	83
106	Why Did Tarenflurbil Fail in Alzheimer's Disease?. Journal of Alzheimer's Disease, 2009, 17, 757-760.	2.6	65
107	Disease-Modifying Approach to the Treatment of Alzheimer's Disease. Drugs and Aging, 2009, 26, 537-555.	2.7	80
108	Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease: drugs targeting β -amyloid and tau protein. Aging Clinical and Experimental Research, 2009, 21, 386-406.	2.9	47

#	ARTICLE	IF	CITATIONS
109	Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease. Current Opinion in Investigational Drugs, 2009, 10, 721-30.	2.3	9
110	Alzheimer's disease: β -secretase inhibitors. Drug Discovery Today: Therapeutic Strategies, 2008, 5, 169-175.	0.5	22
111	Editorial [Hot Topic:Gamma-Secretase Inhibitors and Modulators as a Therapeutic Approach to Alzheimers disease (Guest Editor: Bruno P. Imbimbo)]. Current Topics in Medicinal Chemistry, 2008, 8, 1-1.	2.1	1
112	Therapeutic Potential of γ -Secretase Inhibitors and Modulators. Current Topics in Medicinal Chemistry, 2008, 8, 54-61.	2.1	136
113	Conformation-sensitive Antibodies against Alzheimer Amyloid- β by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide. Journal of Biological Chemistry, 2007, 282, 11436-11445.	3.4	66
114	1-(3,4-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel β -Secretase Modulator, Reduces Brain β -Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 822-830.	2.5	82
115	Discovery of Diaryl Imidazolidin-2-one Derivatives, a Novel Class of Muscarinic M3 Selective Antagonists (Part 2). Journal of Medicinal Chemistry, 2007, 50, 1693-1697.	6.4	14
116	Discovery of Diaryl Imidazolidin-2-one Derivatives, a Novel Class of Muscarinic M3 Selective Antagonists (Part 1). Journal of Medicinal Chemistry, 2007, 50, 1571-1583.	6.4	23
117	In vitro and in vivo profiling of CHF5022 and CHF5074. Pharmacological Research, 2007, 55, 318-328.	7.1	42
118	CHF3381, a N-methyl-D-aspartate Receptor Antagonist and Monoamine Oxidase-A Inhibitor, Attenuates Secondary Hyperalgesia in a Human Pain Model. Journal of Pain, 2006, 7, 565-574.	1.4	33
119	Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β -Amyloid ₁₋₄₂ Secretion. Journal of Medicinal Chemistry, 2005, 48, 5705-5720.	6.4	120
120	Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects. British Journal of Clinical Pharmacology, 2005, 59, 405-414.	2.4	5
121	Mechanistic Pharmacokinetic and Pharmacodynamic Modeling of CHF3381 (2-[(2,3-Dihydro-1H-inden-2-yl)amino]acetamide Monohydrochloride), a Novel N-Methyl-d-aspartate Antagonist and Monoamine Oxidase-A Inhibitor in Healthy Subjects. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 647-657.	2.5	3
122	Pathophysiology of Alzheimer's Disease. Neuroimaging Clinics of North America, 2005, 15, 727-753.	1.0	68
123	Ganstigmine and donepezil improve neurodegeneration in AD11 antinerve growth factor transgenic mice. American Journal of Alzheimer's Disease and Other Dementias, 2004, 19, 153-160.	1.9	22
124	The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opinion on Investigational Drugs, 2004, 13, 1469-1481.	4.1	51
125	P4-342 High throughput screening of β -amyloid secretion inhibitors using homogenous time-resolved fluorescence. Neurobiology of Aging, 2004, 25, S572.	3.1	0
126	O3-06-05 New flurbiprofen analogues, devoid of cyclooxygenase activity, selectively lower β -amyloid ₁₋₄₂ secretion. Neurobiology of Aging, 2004, 25, S64-S65.	3.1	0

#	ARTICLE	IF	CITATIONS
127	High Throughput Screening of γ -Amyloid Secretion Inhibitors Using Homogenous Time-Resolved Fluorescence. Combinatorial Chemistry and High Throughput Screening, 2004, 7, 745-756.	1.1	3
128	The protective effect of ganstigmine against amyloid beta ₂₅₋₃₅ neurotoxicity on chicken cortical neurons is independent from the cholinesterase inhibition. Neuroscience Letters, 2003, 341, 181-184.	2.1	15
129	Safety, Pharmacokinetics, and Pharmacodynamics of CHF 3381, a Novel N-Methyl-D-Aspartate Antagonist, after Single Oral Doses in Healthy Subjects. Journal of Clinical Pharmacology, 2003, 43, 901-911.	2.0	8
130	Toxicity of γ -amyloid vaccination in patients with Alzheimer's disease. Annals of Neurology, 2002, 51, 794-794.	5.3	57
131	γ -Amyloid immunization approaches for Alzheimer's disease. Drug Development Research, 2002, 56, 150-162.	2.9	8
132	Pharmacodynamic-Tolerability Relationships of Cholinesterase Inhibitors for Alzheimer's Disease. CNS Drugs, 2001, 15, 375-390.	5.9	109
133	Central acetylcholinesterase inhibition in Alzheimer patients. Annals of Neurology, 2001, 49, 416-416.	5.3	0
134	Synthesis of New Cardioselective M2 Muscarinic Receptor Antagonists.. Chemical and Pharmaceutical Bulletin, 2000, 48, 1611-1622.	1.3	10
135	A 6-Month, Double-Blind, Placebo-Controlled Trial of Eptastigmine in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2000, 11, 17-24.	1.5	18
136	Hemodynamic effects of MF 10058, a new cardioselective muscarinic M2 receptor antagonist, in conscious dogs. European Journal of Pharmacology, 2000, 406, 93-98.	3.5	3
137	PHARMACODYNAMICS OF A LONG ACTING DEPOT PREPARATION OF AVORELIN IN PATIENTS WITH PROSTATE CANCER. Journal of Urology, 1999, 162, 2019-2023.	0.4	9
138	Two-Year Treatment of Alzheimer's Disease with Eptastigmine. Dementia and Geriatric Cognitive Disorders, 1999, 10, 139-147.	1.5	35
139	Suicide in Two Patients with a Diagnosis of Probable Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1999, 13, 88-90.	1.3	33
140	Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. Neurology, 1999, 52, 700-700.	1.1	44
141	Effect of food on the absorption of eptastigmine. European Journal of Clinical Pharmacology, 1998, 54, 243-247.	1.9	5
142	Acetylcholinesterase assay may predict cognitive response of Alzheimer patients to eptastigmine treatment. European Journal of Clinical Pharmacology, 1998, 54, 809-810.	1.9	1
143	Lack of effect of hexarelin on TRH-induced TSH response in normal adult man. Journal of Endocrinological Investigation, 1998, 21, 239-244.	3.3	1
144	Cardiac Autonomic Dysfunction in Patients with Alzheimer Disease: Possible Pathogenetic Mechanisms. Alzheimer Disease and Associated Disorders, 1998, 12, 356-361.	1.3	44

#	ARTICLE	IF	CITATIONS
145	A 25-Week Placebo-Controlled Study of Eptastigmine in Patients with Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 1998, 12, 313-322.	1.3	18
146	Maximum Tolerated Dose and Pharmacodynamics of Eptastigmine in Elderly Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 610-617.	2.0	20
147	Population pharmacokinetics of rufloxacin in patients with acute exacerbations of chronic bronchitis. <i>European Journal of Pharmaceutical Sciences</i> , 1997, 5, 37-42.	4.0	2
148	The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis. <i>Respiratory Medicine</i> , 1997, 91, 449-460.	2.9	22
149	Acute administration of hexarelin stimulates GH secretion during day and night in normal men. <i>Clinical Endocrinology</i> , 1997, 46, 275-279.	2.4	2
150	Eptastigmine: A Cholinergic Approach to the Treatment of Alzheimer's Disease. , 1997, , 223-230.		4
151	Pharmacodynamic monitoring of eptastigmine in capillary blood. <i>European Journal of Clinical Pharmacology</i> , 1996, 50, 425-427.	1.9	4
152	Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 218-228.	4.7	60
153	A Patient-Side Technique for Real-Time Measurement of Acetylcholinesterase Activity During Monitoring of Eptastigmine Treatment. <i>Therapeutic Drug Monitoring</i> , 1995, 17, 230-238.	2.0	14
154	Relationship Between Pharmacokinetics and Pharmacodynamics of Eptastigmine in Young Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 285-290.	2.0	26
155	Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly. <i>Endocrine Research</i> , 1995, 21, 569-582.	1.2	3
156	Modulation of Growth Hormone-Releasing Activity of Hexarelin in Man. <i>Neuroendocrinology</i> , 1995, 61, 51-56.	2.5	71
157	The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 2692-2696.	3.6	28
158	Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 1090-1094.	3.6	40
159	Mechanism of Action of Hexarelin and GHRP-6: Analysis of the Involvement of GHRH and Somatostatin in the Rat. <i>Neuroendocrinology</i> , 1995, 61, 44-50.	2.5	56
160	Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess. <i>Journal of Endocrinology</i> , 1995, 146, 227-232.	2.6	36
161	The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 674-678.	3.6	36
162	Hexarelin, a potent GHRP analogue: Interactions with GHRH and clonidine in young and aged dogs. <i>Peptides</i> , 1995, 16, 81-86.	2.4	26

#	ARTICLE	IF	CITATIONS
163	Metabolic modulation of the growth hormone-releasing activity of hexarelin in man. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 134-138.	3.4	56
164	The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 674-678.	3.6	29
165	Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 1090-1094.	3.6	35
166	The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 2692-2696.	3.6	26
167	Growth hormone-releasing activity of hexarelin in humans. <i>European Journal of Clinical Pharmacology</i> , 1994, 46, 421-5.	1.9	55
168	Distension-stimulated propagated contractions in human colon. <i>Digestive Diseases and Sciences</i> , 1994, 39, 1955-1960.	2.3	60
169	Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 78, 693-698.	3.6	144
170	Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 78, 693-698.	3.6	110
171	Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 1440-1443.	3.6	59
172	Multiple-dose pharmacokinetics of rufloxacin in patients with cirrhosis. <i>Hepatology</i> , 1993, 18, 847-852.	7.3	8
173	Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. <i>European Journal of Clinical Pharmacology</i> , 1993, 45, 373-6.	1.9	16
174	Prolonged Effects of Cholinesterase Inhibition with Eptastigmine on the Cerebral Blood Flow-Metabolism Ratio of Normal Rats. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1993, 13, 702-711.	4.3	25
175	Impaired colonic motor response to cholinergic stimulation in patients with severe chronic idiopathic (slow transit type) constipation. <i>Digestive Diseases and Sciences</i> , 1993, 38, 1040-1045.	2.3	87
176	Rapid potentiometric determination of cholinesterases in plasma and red cells: Application to eptastigmine monitoring. <i>Chemico-Biological Interactions</i> , 1993, 87, 265-268.	4.0	6
177	Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases. <i>European Journal of Clinical Pharmacology</i> , 1993, 45, S29-S34.	1.9	12
178	Eptastigmine augments basal and GHRH-stimulated growth hormone release in young and old dogs. <i>Life Sciences</i> , 1993, 53, 389-395.	4.3	3
179	Pharmacokinetics of intramuscular dermatan sulfate (MF701) in patients with hip fracture. <i>Thrombosis Research</i> , 1993, 70, S74.	1.7	0
180	The pharmacokinetics and pharmacodynamics of dermatan sulphate MF701 during haemodialysis for chronic renal failure.. <i>British Journal of Clinical Pharmacology</i> , 1993, 35, 335-339.	2.4	4

#	ARTICLE	IF	CITATIONS
181	Pharmacokinetics of rifloxacin in patients with impaired renal function. Antimicrobial Agents and Chemotherapy, 1993, 37, 637-641.	3.2	15
182	Biliary excretion of rifloxacin in humans. Antimicrobial Agents and Chemotherapy, 1993, 37, 2545-2549.	3.2	8
183	The penetration of rifloxacin into sites of potential infection in the respiratory tract. Journal of Antimicrobial Chemotherapy, 1993, 32, 861-866.	3.0	22
184	Effects of magnesium-aluminum hydroxide antacid on absorption of rifloxacin. Antimicrobial Agents and Chemotherapy, 1993, 37, 2212-2216.	3.2	24
185	Multiple-dose pharmacokinetics and safety of rifloxacin in normal volunteers. Antimicrobial Agents and Chemotherapy, 1992, 36, 1296-1301.	3.2	35
186	Steady-State Pharmacokinetics of Rifloxacin in Elderly Patients with Lower Respiratory Tract Infections. Therapeutic Drug Monitoring, 1992, 14, 36-41.	2.0	18
187	Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. Neurobiology of Aging, 1992, 13, S125.	3.1	0
188	High-performance liquid chromatography and preliminary pharmacokinetics of rifloxacin and its metabolites, N-desmethylrifloxacin and rifloxacin sulfoxide, in urine of Rhesus monkey Macaca mulatta. Biomedical Applications, 1992, 573, 168-172.	1.7	7
189	059 Preliminary data on heptastigmine monitoring. Fresenius' Journal of Analytical Chemistry, 1992, 343, 115-115.	1.5	0
190	Gallbladder hypokinesia and normal gastric emptying of liquids in patients with dyspeptic symptoms. Digestive Diseases and Sciences, 1992, 37, 262-267.	2.3	42
191	High performance liquid chromatography and preliminary pharmacokinetics of rifloxacin and its metabolites N-desmethylrifloxacin and rifloxacin sulfoxide in plasma and urine of humans. European Journal of Drug Metabolism and Pharmacokinetics, 1992, 17, 45-49.	1.6	8
192	Pharmacokinetics of rifloxacin once daily in patients with lower respiratory tract infections. Infection, 1992, 20, 89-93.	4.7	9
193	Pharmacokinetics of Rifloxacin in Healthy Volunteers after Repeated Oral Doses. Chemotherapy, 1991, 37, 389-397.	1.6	21
194	Edrophonium chloride for testing colonic contractile activity in man. Acta Physiologica Scandinavica, 1991, 141, 289-293.	2.2	19
195	Efficiency of different criteria for selecting pharmacokinetic multiexponential equations. Biopharmaceutics and Drug Disposition, 1991, 12, 139-147.	1.9	29
196	Kinetics of cholinesterase inhibition by eptastigmine in man. European Journal of Clinical Pharmacology, 1991, 41, 83-84.	1.9	33
197	Inter- and intraindividual variabilities in the pharmacokinetics of rifloxacin after single oral administration to healthy volunteers. Antimicrobial Agents and Chemotherapy, 1991, 35, 390-393.	3.2	52
198	Pharmacokinetics and tissue penetration of rifloxacin, a long acting quinolone antimicrobial agent. Journal of Antimicrobial Chemotherapy, 1991, 28, 905-909.	3.0	37

#	ARTICLE	IF	CITATIONS
199	Effects of cimetropium bromide on gallbladder contraction in response to oral and intraduodenal olive oil. <i>European Journal of Clinical Pharmacology</i> , 1990, 39, 369-372.	1.9	4
200	Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial.. <i>Gut</i> , 1990, 31, 355-358.	12.1	59
201	Bone loss in response to long-term glucocorticoid therapy. <i>Bone and Mineral</i> , 1990, 8, 39-51.	1.9	339
202	New Glucocorticoids. Mechanisms of Immunological Activity at the Cellular Level and in the Clinical Setting. <i>Annals of the New York Academy of Sciences</i> , 1990, 595, 368-382.	3.8	29
203	Inhibition of acetylcholinestense and butyrylcholinesterase after oral administration of heptastigmine in healthy volunteers. <i>European Journal of Pharmacology</i> , 1990, 183, 536.	3.5	4
204	Inhibition of caerulein-induced gall bladder emptying by cimetropium bromide in humans. <i>European Journal of Clinical Pharmacology</i> , 1989, 37, 483-486.	1.9	3
205	Comparative Study of the Effects of Cimetropium Bromide and Atropine on Human Esophageal Motor Functions. <i>Digestion</i> , 1989, 44, 117-123.	2.3	8
206	Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 1989, 3, 267-276.	3.7	24
207	A New Criterion for Selection of Pharmacokinetic Multiexponential Equations. <i>Journal of Pharmaceutical Sciences</i> , 1988, 77, 784-789.	3.3	35
208	Effect of mifentidine on peptone meal-stimulated gastric acid secretion and plasma gastrin levels in duodenal ulcer patients. <i>Agents and Actions</i> , 1988, 25, 22-26.	0.7	4
209	Safety and pharmacokinetics of mifentidine after increasing oral doses in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 1988, 35, 673-676.	1.9	1
210	Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome. <i>European Journal of Clinical Pharmacology</i> , 1988, 33, 571-575.	1.9	13
211	Pharmacokinetics of mifentidine after single and multiple oral administration to healthy volunteers.. <i>British Journal of Clinical Pharmacology</i> , 1988, 26, 407-413.	2.4	5
212	Gastric Acid and Pepsin Secretion after Single Oral Doses of Mifentidine in Healthy Subjects. <i>Scandinavian Journal of Gastroenterology</i> , 1988, 23, 788-792.	1.5	2
213	Manometric Evaluation of Cimetropium Bromide Activity in Patients with the Nutcracker Oesophagus. <i>Scandinavian Journal of Gastroenterology</i> , 1988, 23, 1079-1084.	1.5	23
214	Efficacy of cimetropium bromide as pre-medication for double-contrast barium enema. <i>British Journal of Radiology</i> , 1988, 61, 1087-1088.	2.2	2
215	Colonic mass movements in idiopathic chronic constipation.. <i>Gut</i> , 1988, 29, 1173-1179.	12.1	227
216	Transverse and Sigmoid Colon Motility in Healthy Humans: Effects of Eating and of Cimetropium Bromide. <i>Digestion</i> , 1987, 37, 59-64.	2.3	46

#	ARTICLE	IF	CITATIONS
217	Action of mifentidine on the secretory response to sham feeding and pentagastrin and on serum gastrin in duodenal ulcer patients. European Journal of Clinical Pharmacology, 1987, 32, 555-558.	1.9	8
218	Urinary excretion of cimetropium bromide after multiple oral doses. European Journal of Clinical Pharmacology, 1987, 33, 337-338.	1.9	3
219	Effects of a new heterocyclic glucocorticoid, deflazacort (DFC), on the functions of lymphocytes from patients with rheumatoid arthritis (RA). International Journal of Immunopharmacology, 1987, 9, 133-139.	1.1	9
220	Effects of Pirenzepine and Atropine on Gastroduodenal Motor Patterns in Duodenal Ulcer Patients. Scandinavian Journal of Gastroenterology, 1986, 21, 1046-1050.	1.5	4
221	Discontinuous Oral Absorption of Cimetropium Bromide, a New Antispasmodic Drug. Journal of Pharmaceutical Sciences, 1986, 75, 680-684.	3.3	26
222	Cimetropium bromide as a relaxant for the radiological examination of the stomach and duodenum. Current Medical Research and Opinion, 1986, 10, 319-325.	1.9	6
223	The Use of Cimetropii Bromidum as Premedication for Endoscopy of the Upper Gastro-Intestinal Tract: A Double-Blind Controlled Clinical Trial. Journal of International Medical Research, 1985, 13, 332-337.	1.0	4
224	Effect of single oral doses of prednisone and deflazacort on human lymphocyte distribution and functions. Analysis with monoclonal antibodies. Advances in Experimental Medicine and Biology, 1984, 171, 335-44.	1.6	10